A Randomized, Single Blind, Placebo Controlled Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Single Oral Doses and Repeat Escalating Oral Doses of GSK2251052 in Healthy Adult Subjects

NCT01262885 | Completed Phase 1

• 1 other identifier: 114470
• Study Type: interventional
• Target: 84
• Locations: 1 country
• Sites: 1

Brief Summary

GSK2251052 ((S)-3-(aminomethyl)-7-(3-hydroxypropoxy)-1-hydroxy-1,3-dihydro-2,1-benzoxaborole hydrochloride) is a Gram negative antibacterial compound currently in development for the treatment of hospital acquired Gram negative infection (including E. coli, K. pneumoniae, and Enterobacter spp.) This study will be conducted in two (2) parts, with single oral doses being explored in Part A (500, 1000, and 2000 mg) and repeat oral doses (1000 and 2000 mg, b.i.d.) being explored in Part B. Parts A and B will be single-blind, randomized, placebo-controlled, dose-rising studies in healthy subjects to evaluate the safety, tolerability and pharmacokinetics of oral GSK2251052.

Conditions

Infections, Bacterial

Keywords

pharmacokinetics; tolerability; single dose; antibiotics; repeat dose; GSK2251052; safety

Outcome Measures

Primary Outcomes (2)

• Adverse event reporting, clinical laboratory tests, vital signs, cardiac monitoring, urinalysis, and clinical monitoring/observation.

  within 35 days of first dose

• Plasma AUC(0-t), AUC(0-inf), Cmax, tmax, t1/2, Ae, fe, and CLr of GSK2251052 as data permit.

  within 14 days of first dose

Secondary Outcomes (4)

• AUC(0-t), AUC(0-inf), and Cmax following single dose administration for the assessment of dose proportionality

  within 72 h of dosing

• Trough plasma concentrations

  within 10 days of first dose

• Accumulation based on AUC(Ro) and Cmax (RCmax) and determine the steady-state ratio (Rss)

  within 14 days of first dose

• AUC(0-t)am and Cmax,am following repeat administration at different doses for the assessment of dose proportionality

  within 14 days of first dose

Study Arms (8)

Part A Cohort 1

EXPERIMENTAL

GSK2251052 500 mg (6 subjects), Placebo (1 subject)

Drug: GSK2251052; Drug: Placebo

Part A Cohort 2

EXPERIMENTAL

GSK2251052 1000 mg (6 subjects), Placebo (1 subject)

Drug: GSK2251052; Drug: Placebo

Part A Cohort 3

EXPERIMENTAL

GSK2251052 2000 mg (6 subjects), Placebo (1 subject)

Drug: GSK2251052; Drug: Placebo

Part A Cohort 2 - fed

EXPERIMENTAL

GSK2251052 1000 mg (6 subjects), Placebo (1 subject)

Drug: GSK2251052; Drug: Placebo

Part B Cohort 1

EXPERIMENTAL

Placebo (3 subjects), GSK2251052 (9 subjects) dose to be determined

Drug: GSK2251052; Drug: Placebo

Part B Cohort 2

EXPERIMENTAL

Placebo (3 subjects), GSK2251052 (9 subjects) dose to be determined

Drug: GSK2251052; Drug: Placebo

Part B Cohort 3

EXPERIMENTAL

Placebo (3 subjects), GSK2251052 (9 subjects) dose to be determined

Drug: GSK2251052; Drug: Placebo

Part A Cohort 4

EXPERIMENTAL

Placebo (1 subject), GSK2251052 (6 subjects) dose to be determined

Drug: GSK2251052; Drug: Placebo

Interventions

GSK2251052 DRUG

500 mg tablet, dose levels detailed in Arm description

Part A Cohort 1; Part A Cohort 2; Part A Cohort 2 - fed; Part A Cohort 3; Part A Cohort 4; Part B Cohort 1; Part B Cohort 2; Part B Cohort 3

Placebo DRUG

matching placebo tablet

Part A Cohort 1; Part A Cohort 2; Part A Cohort 2 - fed; Part A Cohort 3; Part A Cohort 4; Part B Cohort 1; Part B Cohort 2; Part B Cohort 3

Eligibility Criteria

• Age: 18 Years - 65 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• AST, ALT, alkaline phosphatase and bilirubin \< or = 1.5xULN (isolated bilirubin \>1.5xULN is acceptable if bilirubin is fractionated and direct bilirubin \<35%).
• Healthy as determined by a responsible and experienced physician, based on a medical evaluation including medical history, physical examination, laboratory tests and cardiac monitoring. A subject with a clinical abnormality or laboratory parameters outside the reference range for the population being studied may be included only if the Investigator and the GSK Medical Monitor agree that the finding is unlikely to introduce additional risk factors and will not interfere with the study procedures. Subjects with coagulation, reticulocyte, or Hgb values outside the normal range should always be excluded from enrollment.
• Male or female between 18 and 65 years of age inclusive, at the time of signing the informed consent.
• A female subject is eligible to participate if she is of:
• Non-childbearing potential defined as pre-menopausal females with a documented tubal ligation or hysterectomy; or postmenopausal defined as 12 months of spontaneous amenorrhea \[in questionable cases a blood sample with simultaneous follicle stimulating hormone (FSH) \> 40 MlU/ml and estradiol \< 40 pg/ml (\<147 pmol/L) is confirmatory\].
• Male subjects with female partners of child-bearing potential must agree to use one of the contraception methods listed in Section 8.1. This criterion must be followed from the time of the first dose of study medication until at least 90 days post-last dose.
• Body weight \> 50 kg and BMI within the range 19 - 32 kg/m2 (inclusive).
• Capable of giving written informed consent, which includes compliance with the requirements and restrictions listed in the consent form.
• QTc, QTcB or QTcF \< 450 msec; or QTc \< 480 msec in subjects with Bundle Branch Block.

You may not qualify if:

• A positive pre-study Hepatitis B surface antigen or positive Hepatitis C antibody result within 3 months of screening
• Current or chronic history of liver disease, or known hepatic or biliary abnormalities (with the exception of Gilbert's syndrome or asymptomatic gallstones).
• A positive pre-study drug/alcohol screen.
• A positive test for HIV antibody.
• History of regular alcohol consumption within 6 months of the study defined as an average weekly intake of \>21 units for males or \>14 units for females. One unit is equivalent to 8 g of alcohol: a half-pint (\~240 ml) of beer, 1 glass (125 ml) of wine or 1 (25 ml) measure of spirits.
• The subject has participated in a clinical trial and has received an investigational product within the following time period prior to the first dosing day in the current study: 30 days, 5 half-lives or twice the duration of the biological effect of the investigational product (whichever is longer).
• Exposure to more than four new chemical entities within 12 months prior to the first dosing day.
• Use of prescription or non-prescription drugs, including vitamins, herbal and dietary supplements (including St John's Wort) within 7 days (or 14 days if the drug is a potential enzyme inducer) prior to the first dose of study medication, unless in the opinion of the Investigator and GSK Medical Monitor the medication will not interfere with the study procedures or compromise subject safety.
• History of sensitivity to any of the study medications, or components thereof or a history of drug or other allergy that, in the opinion of the investigator or GSK Medical Monitor, contraindicates their participation.
• Where participation in the study would result in donation of blood or blood products in excess of 500 mL within a 56 day period.
• Pregnant females as determined by positive serum or urine hCG test at screening or prior to dosing.
• Lactating females.
• Unwillingness or inability to follow the procedures outlined in the protocol.
• Subject is mentally or legally incapacitated.
• History of sensitivity to heparin or heparin-induced thrombocytopenia.

Sponsors & Collaborators

• GlaxoSmithKline: lead

Study Sites (1)

GSK Investigational Site

Adelaide, South Australia, 5000, Australia

Location

Related Links

• Results for study 114470 can be found on the GSK Clinical Study Register.

MeSH Terms

Conditions

Bacterial Infections

Interventions

3-(aminomethyl)-7-(3-hydroxypropoxy)-1-hydroxy-1,3-dihydro-2,1-benzoxaborole

Condition Hierarchy (Ancestors)

Bacterial Infections and Mycoses; Infections

Study Officials

• GSK Clinical Trials

  GlaxoSmithKline

  STUDY DIRECTOR

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: RANDOMIZED
• Masking: SINGLE
• Who Masked: PARTICIPANT
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: December 16, 2010
• First Posted: December 17, 2010
• Study Start: October 7, 2010
• Primary Completion: August 25, 2011
• Study Completion: August 25, 2011
• Last Updated: June 28, 2017

Record last verified: 2017-06

Locations

AU (1)